Table 2:

Treatment variables

	MISTIE (n=250)	Medical (n=249)	p value
Ictus to randomisation time (hours)	47 (33–60)	46 (36–58)	0·817
Ictus to end of treatment (EOT) time (hours)*	123 (104–150)	115 (103–127)	<0·0001
MISTIE procedure duration (hours)	1 (1–1)	NA	NA
Number of alteplase doses	4 (2–6)	NA	NA
EOT CT
ICH volume (mL)	12·5 (7·6–21·0)†	43·7 (33·6–56·3)†	<0·0001
IVH volume (mL)	0·2 (0–1·5)	0·3 (0–1·9)	0·137
EOT ICH remaining ≤15 mL	148 (59·7%)	2 (0·8%)	<0·0001
Withdrawal of care	26 (10·4%)	35 (14·1%)	0·213
Days in ICU	10 (7–17)	10 (5–16)	0·460
Days to return home	55 (34–105)	62 (35–100)	0·846
ICP events monitored
% subjects with any ICP ≥20 mm Hg	34 (13·6%)	38 (15·3%)	0·598
% subjects with any CPP <70 mm Hg	9/34 (26·5%)	22/38 (57·9%)	0·007
% ICP readings ≥20 mm Hg†	23/690 (3·3%)	67/711 (9·4%)	0·01
% CPP readings <70 mm Hg†	64/690 (9·3%)	159/711 (22·4%)	0·04
One or more ICP therapies	25/34 (73·5%)	26/38 (68·4%)	0·634

Data are median (IQR), mean (SD), or n/N (%). NA=not applicable. ICH=intracerebral haemorrhage. IVH=intraventricular haemorrhage. ICU=intensive care unit. ICP=intracranial pressure. CPP=cerebral perfusion pressure.

^*End of treatment time calculated as 24 h after last dose for patients in the MISTIE group who received alteplase and as the sum of randomisation time plus median surgical end of treatment time for patients in the standard medical care group. This achieved a virtual dosing endpoint without alteplase dosing for each individual patient in the standard medical care groups.

^†Adjusted for number of readings per patient.

^‡Data were available for 240 patients in the MISTIE group and 238 patients in the standard medical care group. Additional outcome variable data are included in the appendix.